An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Advanced Cancer
Latest Information Update: 28 Apr 2023
At a glance
- Drugs Ocifisertib (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
Most Recent Events
- 06 May 2022 Status changed from active, no longer recruiting to completed.
- 25 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2020 New trial record